Evaluation of safety and efficacy of focal intramuscular injection of wharton’s gelly-derived mesenchymal stem cell in Duchenne muscular dystrophy pediatrics between 5 to 12 years old

Sinacell Company0 个研究点目标入组 5 人开始时间: 待定最近更新: 2023年2月7日

适应症

试验速览

暂无简介。

•Age between 5 to 12
•Genetic evidence of Duchenne disease as a cause of myopathy
•The patient's ability to walk is not completely lost and the use of assistive devices such as canes and walkers is not permanent.
•The patient's muscle strength is decreasing
•Willingness and satisfaction to participate in the study by the patient's legal guardian in decision making and willingness to participate regularly in follow-up courses
•Weight between 15 to 35

•Advanced motor impairment leading to permanent use of crutches, walkers and wheelchairs
•A history of known malignancy
•History of associated genetic and non-genetic degenerative diseases
•A history of any other acute or chronic illness that, at the discretion of the clinician responsible for implementing the plan, prevents the patient from entering the study.

发起方

Sinacell Company